Shopping Cart
- Remove All
- Your shopping cart is currently empty
LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | 249 € | In Stock | |
5 mg | 511 € | In Stock | |
10 mg | 828 € | In Stock | |
25 mg | 1.225 € | In Stock | |
50 mg | 1.643 € | In Stock |
Description | LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer. |
Alias | hLIV22 |
Molecular Weight | 146.96 kDa |
Cas No. | 1629760-28-6 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.